Friday, 17 September 2021


Mylan signs a settlement agreement with OSI Pharma

25 July 2013 | News | By BioSpectrum Bureau

IMS Health data quoted by Mylan shows that Erlotinib had US sales of about $638.7 million for the 12 months ending March 31, 2013

IMS Health data quoted by Mylan shows that Erlotinib had US sales of about $638.7 million for the 12 months ending March 31, 2013

Singapore: US generics major Mylan has entered into a settlement agreement with OSI Pharmaceuticals, a subsidiary of Japan's Astellas, Pfizer and Roche subsidiary Genentech that will resolve patent litigation related to erlotinib hydrochloride tablets, 25mg, 100mg and 150mg.

This is the generic version of Tarceva and is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Under the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement have been kept confidential and the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission.

Erlotinib had US sales of about $638.7 million for the 12 months ending March 31, 2013, according to IMS Health data quoted by Mylan.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account